Ultragenyx is selling a second rare pediatric Priority Review Voucher within a week, this time for $203M, following FDA approval of FAYUVI (rebisufligene etisparvovec-hopf). The transaction brings its combined voucher proceeds to $413M, continuing a fast monetization pace tied to pediatric gene-therapy approvals. FAYUVI generated the voucher after FDA approval as the first treatment for mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). The company said voucher sales provide non-dilutive capital that can support further pipeline development and strengthens its route to profitability. Ultragenyx previously agreed to sell the voucher earned from approval of GENGLYCOS for glycogen storage disease type Ia for $210M, bringing the total across the two sales to $413M. For the market, the report reinforces how the rare pediatric PRV program is functioning as a recurring financing mechanism—particularly for developers seeking additional clinical optionality without diluting shareholders.